End-stage liver fibrosis with portal hypertension; ascites, varices, and encephalopathy define decompensation.
Also known as: cirrhosis, decompensated cirrhosis, ascites, hepatic encephalopathy, portal hypertension
Overview
Diffuse hepatic fibrosis with regenerative nodules, representing the end stage of chronic liver injury from any cause. Compensated cirrhosis is asymptomatic; decompensated cirrhosis is defined by ascites, variceal bleeding, hepatic encephalopathy, or jaundice.
Epidemiology
Affects ~600,000 US adults; 9th leading cause of death (~52,000 deaths/yr). Common etiologies in US: MASLD/MASH, alcohol-associated liver disease, chronic HCV (declining with DAAs), chronic HBV. Mortality dependent on Child-Pugh and MELD scores; 1-yr mortality 1-3% compensated, 20-60% decompensated.
Try two board-style Cirrhosis questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1GastrointestinalMedium
A 45-year-old man with Child-Pugh class B cirrhosis develops confusion, disorientation, and asterixis two days after an upper gastrointestinal bleed. His serum ammonia is elevated. Which of the following is the most appropriate pharmacologic regimen?
AOral zinc supplementation
BLactulose and rifaximin
CIntravenous albumin
DIntravenous mannitol
EOral neomycin sulfate
Reveal answer & full explanation
Correct answer: B — Lactulose and rifaximin
AOral zinc supplementation
BLactulose and rifaximin✓
CIntravenous albumin
DIntravenous mannitol
EOral neomycin sulfate
Why Lactulose and rifaximin is correct
Confusion and asterixis in a patient with cirrhosis after a GI bleed indicate hepatic encephalopathy precipitated by the nitrogen load from luminal blood
Lactulose acidifies colonic contents, trapping ammonia as nonabsorbable NH4+ for fecal excretion, and is the first-line agent for an acute episode per AASLD/EASL guidance
Rifaximin is the preferred add-on antibiotic, used for inadequate response to lactulose and to prevent recurrence; of the options listed, only this choice contains lactulose, making it the best regimen here
Why the others are wrong
Intravenous albumin — used for spontaneous bacterial peritonitis and hepatorenal syndrome to support oncotic pressure, not to lower ammonia in encephalopathy (confused-with-other-cirrhosis-complication)
Oral zinc supplementation — zinc deficiency can aggravate encephalopathy and repletion is only an adjunct; it does not treat the acute episode (right-idea-wrong-priority)
Oral neomycin sulfate — an older nonabsorbable antibiotic largely abandoned for hepatic encephalopathy because of ototoxicity and nephrotoxicity; rifaximin is the safer preferred agent (outdated-therapy)
Intravenous mannitol — an osmotic agent used for intracranial hypertension from cerebral edema in acute liver failure, which tempts when an elevated ammonia is linked to brain swelling; this patient has chronic cirrhosis, where clinically significant cerebral edema is uncommon, and mannitol neither lowers ammonia nor clears the nitrogen load from luminal blood (confused-with-acute-liver-failure)
Question 2GastrointestinalMedium
A 65-year-old man with cirrhosis and ascites is admitted with diffuse abdominal pain, fever, and worsening confusion. Diagnostic paracentesis shows an ascitic fluid polymorphonuclear (PMN) count of 350 cells/mm3. Which of the following is the most appropriate initial treatment?
AOral ciprofloxacin
BTherapeutic paracentesis
CIntravenous gentamicin
DIntravenous vancomycin
EIntravenous cefotaxime
Reveal answer & full explanation
Correct answer: E — Intravenous cefotaxime
AOral ciprofloxacin
BTherapeutic paracentesis
CIntravenous gentamicin
DIntravenous vancomycin
EIntravenous cefotaxime✓
Why Intravenous cefotaxime is correct
An ascitic fluid PMN count of at least 250 cells/mm3 establishes spontaneous bacterial peritonitis (SBP), and empiric antibiotics are started immediately without waiting for culture (cultures are negative in roughly half of cases)
A third-generation cephalosporin such as intravenous cefotaxime is first-line therapy; intravenous albumin is added to reduce the risk of hepatorenal syndrome and death
Why the others are wrong
Intravenous vancomycin — covers gram-positive organisms only and misses the enteric gram-negative bacilli, chiefly Escherichia coli and Klebsiella, that cause most SBP, so it is inadequate empiric coverage (reflex broad-spectrum antibiotic)
Oral ciprofloxacin — an oral fluoroquinolone is used for SBP prophylaxis or uncomplicated cases, not for an acute episode with encephalopathy and systemic signs, where intravenous therapy is required (confused-with-prophylaxis)
Therapeutic paracentesis — large-volume paracentesis treats tense ascites, not the infection, and does nothing for the bacterial peritonitis (right-setting-wrong-target)
Intravenous gentamicin — an aminoglycoside covers the enteric gram-negative bacilli that cause most SBP, but it is avoided in cirrhosis because its nephrotoxicity adds to the already high risk of acute kidney injury and hepatorenal syndrome that accompanies SBP (right-spectrum-wrong-patient)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Cirrhosis (Ascites, Varices, Encephalopathy) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Peritoneal carcinomatosis or TB peritonitis — Low SAAG (<1.1) with high total protein; cytology for carcinomatosis; lymphocyte-predominant fluid with high ADA and AFB for TB
Protein-losing enteropathy — Hypoalbuminemia without liver dysfunction; alpha-1 antitrypsin clearance
Diagnostic workup
Diagnostic criteria
Histologic gold standard but rarely needed; clinical, biochemical, and imaging features are usually sufficient. Compensated vs decompensated cirrhosis based on presence of ascites, variceal bleeding, hepatic encephalopathy, or jaundice.
Labs
LFTs — AST/ALT often mildly elevated or even normal; AST > ALT and AST:ALT >2:1 suggests alcohol; alk phos and GGT cholestatic
Bilirubin, albumin, INR (synthetic function — used for Child-Pugh and MELD)
Triphasic CT or MRI with contrast for HCC surveillance and characterization
Upper endoscopy at diagnosis to screen for varices (or non-invasive criteria — Baveno VI/VII: liver stiffness <20 kPa + platelets >150,000 allows deferral)
MELD/Child-Pugh scoring for prognostication and transplant evaluation
Diagnostic algorithm
Child-Pugh Variable
1 point
2 points
3 points
Bilirubin (mg/dL)
<2
2-3
>3
Albumin (g/dL)
>3.5
2.8-3.5
<2.8
INR
<1.7
1.7-2.3
>2.3
Ascites
None
Mild (diuretic responsive)
Moderate-severe (refractory)
Encephalopathy
None
Grade 1-2
Grade 3-4
Class A
5-6 points; 1-yr survival ~100%
Class B
7-9 points; 1-yr survival ~80%
Class C
10-15 points; 1-yr survival ~45%
Child-Pugh score for cirrhosis severity. MELD (MELD 3.0 in the US since 2023) is used for transplant allocation but Child-Pugh remains useful clinically.
Treatment
First-line
Treat underlying cause: alcohol cessation, antiviral therapy (HBV nucleoside analogues, HCV DAAs), weight loss for MASH, immunosuppression for autoimmune hepatitis, phlebotomy for hemochromatosis, chelation for Wilson
Vaccinate against HAV, HBV, pneumococcus, influenza, COVID-19
Nutritional support — late-evening snack to reduce muscle catabolism; protein 1.2-1.5 g/kg/day; supplementation of B12, folate, thiamine, vitamin D
HCC surveillance: ultrasound ± AFP every 6 months
Variceal screening EGD (or non-invasive criteria)
Ascites
Sodium restriction <2 g/day
Diuretics: spironolactone (start 100 mg) + furosemide (start 40 mg) in 100:40 ratio; titrate to maintain ratio
Tense (grade 3) ascites: therapeutic large-volume paracentesis first, then continue sodium restriction and diuretics; give albumin 6-8 g/L removed when >5 L is drained
Refractory ascites needing repeated LVP: TIPS preferred if a suitable candidate (avoid in recurrent or severe encephalopathy, EF<60%, advanced age, MELD >18); otherwise serial LVP with albumin; refer for liver transplantation
SBP prophylaxis: norfloxacin or ciprofloxacin daily if ascitic protein <1.5 g/dL plus poor liver function or prior SBP
SBP treatment: IV third-generation cephalosporin (ceftriaxone 2 g/day or cefotaxime 2 g q8h) × 5-7 days + albumin 1.5 g/kg day 1, 1 g/kg day 3 (reduces hepatorenal syndrome and mortality)
Esophageal varices
Primary prophylaxis for medium/large varices: non-selective beta-blocker (propranolol, nadolol, carvedilol) titrated to HR 55-60 OR serial EVL (band ligation)
Acute variceal bleed: octreotide infusion + ceftriaxone 1 g + EGD with EVL within 12 h + restrictive transfusion (Hgb ~7); early TIPS for high-risk patients
Secondary prophylaxis after bleed: NSBB + serial EVL until eradication
Lactulose 25 mL PO q1-2h until at least 2 soft bowel movements, then titrate to 2-3 soft stools per day; acidifies the colon, trapping NH3 as non-absorbable NH4+, and its cathartic effect speeds ammonia clearance
Rifaximin 550 mg BID (nonabsorbable antibiotic that reduces ammonia-producing gut bacteria) — add for recurrent or refractory encephalopathy (Bass NM, NEJM 2010 RFHE3001 trial)
Avoid sedatives, opioids, benzodiazepines
Adequate protein intake — DO NOT restrict (worsens sarcopenia)
Second-line / adjunct
TIPS (transjugular intrahepatic portosystemic shunt) for refractory ascites, refractory variceal bleeding, or hepatic hydrothorax — risks include precipitating encephalopathy
Liver transplantation — definitive treatment for decompensated cirrhosis; refer when MELD ≥15 or after a decompensation event; MELD sets waitlist priority (MELD 3.0 for US allocation since 2023), but in alcohol-associated cirrhosis candidacy hinges on sustained abstinence, AUD treatment and psychosocial evaluation rather than a MELD cutoff
Hepatorenal syndrome: terlipressin (now FDA-approved) + albumin OR norepinephrine + albumin; bridge to transplant
Coagulopathy (decreased synthesis of factors; balanced — not as protective as INR suggests; balance rebalances toward thrombosis with portal vein thrombosis risk)
Sarcopenia, malnutrition
Sepsis, immune dysfunction
Cardiopulmonary: cirrhotic cardiomyopathy
Endocrine: hypogonadism, glucose intolerance
PANCE pearls
SAAG (serum-ascites albumin gradient) ≥1.1 g/dL = portal hypertension as cause of ascites; <1.1 = other (carcinomatosis, TB, pancreatic, nephrotic). With SAAG ≥1.1, ascitic total protein <2.5 g/dL points to cirrhosis, while ≥2.5 g/dL points to cardiac ascites or Budd-Chiari.
Spontaneous bacterial peritonitis: ascitic PMN ≥250/mm³ regardless of culture — start empiric ceftriaxone and albumin immediately.
Albumin in SBP (1.5 g/kg day 1, 1 g/kg day 3) reduces hepatorenal syndrome and mortality (Sort, NEJM 1999).
Restrictive transfusion (Hgb ~7) in variceal bleed reduces rebleed and mortality vs liberal (Villanueva, NEJM 2013).
Early TIPS within 72 h of variceal bleed for high-risk patients (Child-Pugh C <14, or B with active bleed at EGD) reduces mortality (García-Pagán, NEJM 2010).
Lactulose first-line for hepatic encephalopathy; add rifaximin for recurrence (Bass NM, NEJM 2010 RFHE3001 trial).
Do NOT restrict protein in cirrhosis — worsens sarcopenia and outcomes.
INR overestimates bleeding risk in cirrhosis; coagulopathy is REBALANCED — thrombosis risk is real.
MELD (bilirubin, INR, creatinine) predicts 90-day mortality; MELD-Na adds serum sodium, and MELD 3.0 (adds albumin and female sex) has been used for US transplant allocation since July 2023; Child-Pugh remains useful at the bedside.
Acute kidney injury in cirrhosis differential: pre-renal (volume depletion, response to albumin), HRS (no response to albumin, no other cause), ATN, drug-induced — albumin challenge differentiates.
Avoid NSAIDs (renal failure), aminoglycosides, ACEi/ARBs in advanced cirrhosis.
West Haven grades of hepatic encephalopathy (grade I is covert; II-IV are overt): I = trivial lack of awareness, shortened attention span; II = lethargy, disorientation to time, personality change, asterixis; III = somnolence to semistupor but arousable, gross disorientation, bizarre behavior; IV = coma.
References
AASLD 2021 Ascites — Biggins SW et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74:1014-1048
AASLD 2014 HE — Vilstrup H et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL. Hepatology 2014;60:715-735
Baveno VII — de Franchis R et al. Baveno VII — Renewing consensus in portal hypertension. J Hepatol 2022;76:959-974
RFHE3001 (Rifaximin HE) — Bass NM et al. Rifaximin Treatment in Hepatic Encephalopathy. NEJM 2010;362:1071-1081
Practice Gastrointestinal questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.